Agios Pharmaceuticals (AGIO)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Agios Pharmaceuticals (AGIO)
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
Key Insights
Critical company metrics and information
Share Price
$61.00Market Cap
$3.48 BillionTotal Outstanding Shares
57.03 Million SharesTotal Employees
386Dividend
No dividendIPO Date
July 24, 2013SIC Description
Pharmaceutical PreparationsHomepage
https://www.agios.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Investing Activities | $508.11 Million |
Net Cash Flow From Operating Activities | $-329.16 Million |
Net Cash Flow From Operating Activities, Continuing | $-329.16 Million |
Net Cash Flow | $189.40 Million |
Net Cash Flow From Financing Activities | $10.45 Million |
Net Cash Flow From Investing Activities, Continuing | $508.11 Million |
Net Cash Flow, Continuing | $189.40 Million |
Net Cash Flow From Financing Activities, Continuing | $10.45 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Benefits Costs and Expenses | $-694.56 Million |
Net Income/Loss Available To Common Stockholders, Basic | $674.31 Million |
Diluted Earnings Per Share | $11.66 |
Operating Income/Loss | $-406.98 Million |
Costs And Expenses | $439.85 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Net Income/Loss Attributable To Parent | $674.31 Million |
Income/Loss From Continuing Operations After Tax | $674.31 Million |
Revenues | $32.87 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Diluted Average Shares | $115.12 Million |
Cost Of Revenue | $3.49 Million |
Selling, General, and Administrative Expenses | $140.39 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Net Income/Loss | $674.31 Million |
Gross Profit | $29.38 Million |
Basic Earnings Per Share | $11.86 |
Income/Loss From Continuing Operations Before Tax | $727.43 Million |
Operating Expenses | $436.36 Million |
Basic Average Shares | $113.62 Million |
Research and Development | $295.96 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Inventory | $26.43 Million |
Current Assets | $1.07 Billion |
Assets | $1.79 Billion |
Liabilities And Equity | $1.79 Billion |
Current Liabilities | $119.45 Million |
Accounts Payable | $17.14 Million |
Equity Attributable To Parent | $1.63 Billion |
Cash | $1.70 Billion |
Wages | $17.69 Million |
Liabilities | $165.12 Million |
Noncurrent Liabilities | $45.67 Million |
Other Non-current Assets | $705.79 Million |
Other Current Liabilities | $84.62 Million |
Fixed Assets | $11.82 Million |
Noncurrent Assets | $717.61 Million |
Equity | $1.63 Billion |
Equity Attributable To Noncontrolling Interest | $0.00 |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.